$INCY

Stein Steven H sold $215K of INCY

Stein Steven H (CMO & Head of Late-Stage Dev.) sold 1,877 shares of INCYTE CORP (INCY) at $114.73 ($0.22M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stein Steven H
Published Jul 20, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosed sale amount and execution details are new, but the presence of a pre-arranged 10b5-1 plan makes it less likely to be a fresh negative fundamental signal.

02

Market read

Traders may treat this as routine insider activity with limited immediate impact on valuation, but it can be used to monitor insider behavior trends.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-20, covering a sale executed 2026-07-16.

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by the CMO and Head of Late-Stage Development.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows CMO Steven H Stein sold 1,877 shares on 2026-07-16 for about $215,348 under a 10b5-1 plan.

Expected impact

Minimal, unless follow-on filings show unusual selling outside 10b5-1 or a pattern change.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies the sale was under a pre-arranged 10b5-1 plan, which typically reduces interpretive signal.

Market effects

No direct sector read-across; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management de-risking ahead of catalysts, so traders may watch for clustering of similar sales.

Key entities

  • INCY

    Incyte Corporation, the subject of the Form 4 insider transaction.

  • Stein Steven H

    CMO and Head of Late-Stage Development who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.